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Abstract  
 
 
Objectives: To update the EULAR recommendations for the management of systemic lupus erythematosus 
(SLE) based upon emerging new evidence.   
Methods: Systematic literature review (01/2007-12/2017) followed by modified Delphi method to form 
questions, elicit expert opinions and reach consensus. 
Results: Treatment in SLE aims at remission or low disease activity and prevention of flares. 
Hydroxychloroquine is recommended in all lupus patients, at a dose not exceeding 5mg/kg real body weight. 
During chronic maintenance treatment, glucocorticoids should be minimized to less than 7.5 mg/day 
(prednisone equivalent) and, when possible, withdrawn. Appropriate initiation of immunomodulatory agents 
(methotrexate, azathioprine, mycophenolate) can expedite the tapering/discontinuation of glucocorticoids. In 
persistently active or flaring extrarenal disease, add-on belimumab should be considered; rituximab may be 
considered in organ-threatening, refractory disease. Updated specific recommendations are also provided for 
cutaneous, neuropsychiatric, haematological and renal disease. SLE patients should be assessed for their 
antiphospholipid antibody status, infectious and cardiovascular diseases risk profile, and preventative 
strategies be tailored accordingly.  
Conclusion: The recommendations provide physicians and patients with updated consensus guidance on the 
management of SLE, combining evidence-base and expert-opinion. 
 
 
Keywords: Systemic lupus erythematosus, treatment, lupus nephritis 
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Introduction 
Systemic lupus erythematosus (SLE) has variable presentation, course and prognosis. The wide acceptance 
and popularity of the first EULAR recommendations for its management, published in 2008,1 prompted the 
subsequent development of specific recommendations regarding monitoring, neuropsychiatric and renal 
disease, as well as for pregnancy and women’s health in lupus.2-5 Since these publications, new data have 
emerged on treatment strategies and validated goals of treatment, alternative regimens of glucocorticoids 
(GC), “multitargeted” therapy with the use of calcineurin inhibitors (CNIs) in lupus nephritis (LN), and the 
approval of the first biologic therapy for SLE. These advances called for an update of the EULAR 
recommendations for lupus, capitalizing on the strengths of and experience from the previous projects.6  
 
Methods 
After approval by the EULAR Executive Committee, the convenor (DB) and methodologist (GB) invited a 
Task Force to work on this update; two fellows (AF, MK) undertook the systematic literature review (SLR). 
The EULAR standardised operating procedures7 and the Appraisal of Guidelines Research and Evaluation 
instrument (AGREE II)8 were followed. Applying a Delphi-based methodology, 14 research questions were 
selected for SLR (Supplementary Table 1). PubMed was screened using strings of relevant terms. Since 
this was an update of the previous 2007 recommendations, the SLR considered all English-language 
publications from 01/2007 until 12/2017, with two exceptions: i) treatment of skin disease, wherein an 
unrestricted date search was performed, and ii) renal disease, wherein search was limited to the period 
01/2012 – 12/2017 (since the EULAR recommendations for LN were published in 2012). Pertinent articles, 
identified by manual search within the reference list of the originally retrieved publications, were also 
included. All retrieved items were refined based on article type, abstract, full-text content and number of 
included patients. The final level of evidence and grading of recommendations considered also the body of 
evidence that had informed the previous sets of EULAR recommendations for the management of SLE, as 
the convenor, methodologist and several of the panellists had also participated in the latter. A detailed 
presentation of the SLR results is given in Supplementary Tables 2 and 3. Evidence was categorised based 
on the design and validity of available studies and the strength of the statements was graded (see 
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Supplementary Table 4). After rounds of discussions, the committee reached a consensus of 33 final 
statements, grouped in 4 broad categories (Goals of Treatment, Treatment of SLE, Specific manifestations, 
Comorbidities - Table 1). Each Task Force member rated their agreement with each statement. 
 
Table 1. Recommendations for the management of patients with systemic lupus erythematosus 
 
 
Overarching principles 
 SLE is a multisystem disease - occasionally limited to one or few organs - diagnosed on clinical grounds 
in the presence of characteristic serologic abnormalities. 
 SLE care is multidisciplinary, based on a shared patient-physician decision, and should consider 
individual, medical and societal costs.  
 Treatment of organ-/life-threatening SLE includes an initial period of high-intensity immunosuppressive 
therapy to control disease activity, followed by a longer period of less intensive therapy to consolidate 
response and prevent relapses. 
 Treatment goals include long-term patient survival, prevention of organ damage and optimization of 
health-related quality of life. 
Recommendation/Statement Level of 
agreement, 
mean (SD) 
1. Goals of treatment  
1.1 Treatment in SLE should aim at remission or low disease activity (2b/B) and prevention of 
flares (2b/B) in all organs, maintained with the lowest possible dose of glucocorticoids. 10.0 (0) 
1.2 Flares of SLE can be treated according to the severity of organ(s) involvement by adjusting 
ongoing therapies (glucocorticoids, immunomodulating agents) to higher doses, switching, 
or adding new therapies (2b/C). 
9.95 (0.22) 
2. Treatment of SLE  
2.1 Hydroxychloroquine (HCQ)  
2.1.1 HCQ is recommended for all patients with SLE (1b/A), unless contraindicated, at a 
dose not exceeding 5 mg/kg/real BW (3b/C). 
9.65 (1.11) 
2.1.2 In the absence of risk factors for retinal toxicity, ophthalmologic screening (by visual 
fields examination and/or spectral domain-optical coherence tomography) should be 
9.75 (0.70) 
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performed at baseline, after 5 years, and yearly thereafter (2b/B). 
2.2 Glucocorticoids (GC)  
2.2.1 GC can be used at doses and route of administration that depend on the type and 
severity of organ involvement (2b/C). 
9.95 (0.22) 
2.2.2 Pulses of intravenous methylprednisolone (usually 250–1000 mg per day, for 1–3 days) 
provide immediate therapeutic effect and enable the use of lower starting dose of oral 
GC (3b/C). 
9.85 (0.36) 
2.2.3   For chronic maintenance treatment, GC should be minimized to less than 7.5 mg/day 
(prednisone equivalent) (1b/B) and, when possible, withdrawn.  
9.65 (0.65) 
2.2.4 Prompt initiation of immunomodulatory agents can expedite the 
tapering/discontinuation of GC (2b/B). 9.90 (0.30) 
2.3 Immunosuppressive therapies  
2.3.1 In patients not responding to HCQ (alone or in combination with GC) or patients 
unable to reduce GC below doses acceptable for chronic use, addition of 
immunomodulating/immunosuppressive agents such as methotrexate, (1b/B) 
azathioprine (2b/C) or mycophenolate (2a/B) should be considered. 
9.85 (0.48) 
2.3.2 Immunomodulating/immunosuppressive agents can be included in the initial therapy in 
cases of organ-threatening disease (2b/C). 
9.85 (0.48) 
2.3.3 Cyclophosphamide can be used for severe organ- or life-threatening SLE as well as 
“rescue” therapy in patients not responding to other immunosuppressive agents (2b/C).  9.90 (0.30) 
2.4 Biologics   
2.4.1 In patients with inadequate response to standard-of-care (combinations of HCQ and 
GC with or without immunosuppressive agents), defined as residual disease activity not 
allowing tapering of glucocorticoids and/or frequent relapses, add-on treatment with 
belimumab should be considered (1a/A). 
9.20 (0.81) 
2.4.2 In organ-threatening disease refractory or with intolerance/contraindications to 
standard immunosuppressive agents, rituximab can be considered (2b/C). 
9.85 (0.48) 
3 Specific manifestations  
3.1 Skin disease  
3.1.1 First-line treatment of skin disease in SLE includes topical agents (GC, calcineurin 
inhibitors) (2b/B), antimalarials (HCQ, quinacrine) (1a/A) and/or systemic GC (4/C). 10.0 (0) 
3.1.2 In non-responsive cases or cases requiring high-dose GC, methotrexate (3a/B), 
retinoids (4/C), dapsone (4/C) or mycophenolate (4/C) can be added. 9.85 (0.48) 
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3.2 Neuropsychiatric disease  
3.2.1 Attribution to SLE - as opposed to non-SLE - related neuropsychiatric manifestations, 
is essential and can be facilitated by neuroimaging, investigation of cerebrospinal fluid, 
consideration of risk factors [type and timing of the manifestation in relation to the 
onset of lupus, patient age, non-neurological lupus activity, presence of 
antiphospholipid antibodies (aPL)] and exclusion of confounding factors (2b/C).  
9.65 (0.85) 
3.2.2 Treatment of SLE-related neuropsychiatric disease includes 
glucocorticoids/immunosuppressive agents for manifestations considered to reflect an 
inflammatory process (1b/A), and antiplatelet/anticoagulants for 
atherothrombotic/aPL-related manifestations (2b/C). 
9.85 (0.48) 
3.3 Hematologic disease  
3.3.1 Acute treatment of lupus thrombocytopenia includes high-dose GC (including pulses 
of intravenous methylprednisolone) (4/C) and/or intravenous immunoglobulin G (4/C). 9.95 (0.22) 
3.3.2 For maintenance of response, immunosuppressive/GC-sparing agents such as 
mycophenolate (2b/C), azathioprine (2b/C), or cyclosporine (4/C) can be used. 9.75 (0.62) 
3.3.3 Refractory cases can be treated with rituximab (3a/C) or cyclophosphamide (4/C).   
9.65 (0.73) 
3.4 Renal disease  
3.4.1 Early recognition of signs of renal involvement and - when present - performance of a 
diagnostic renal biopsy are essential to ensure optimal outcomes (2b/B). 9.95 (0.22) 
3.4.2 Mycophenolate (1a/A) or low-dose IV cyclophosphamide (2a/B) are recommended 
as initial (induction) treatment, as they have the best efficacy/toxicity ratio. 9.85 (0.36) 
3.4.3 In patients at high risk for renal failure (reduced glomerular filtration rate, histologic 
presence of fibrous crescents or fibrinoid necrosis, or tubular atrophy/interstitial 
fibrosis], similar regimens may be considered but high-dose IV cyclophosphamide 
can also be used (1b/A).  
9.45 (0.80) 
3.4.4 For maintenance therapy, mycophenolate (1a/A) or azathioprine (1a/A) should be 
used. 9.75 (0.62) 
3.4.5 In cases with stable/improved renal function but incomplete renal response (persistent 
proteinuria >0.8-1 g/24h after at least one year of immunosuppressive treatment), 
repeat biopsy can distinguish chronic from active kidney lesions (4/C). 
9.85 (0.48) 
3.4.6 Mycophenolate may be combined with low dose of a calcineurin inhibitor in severe 9.50 (0.81) 
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nephrotic syndrome (2b/C) or incomplete renal response (4/C), in the absence of 
uncontrolled hypertension, high chronicity index at kidney biopsy and/or reduced GFR. 
4 Comorbidities  
4.1 Antiphospholipid syndrome  
4.1.1 All SLE patients should be screened at diagnosis for aPL (1a/A). 10.0 (0) 
4.1.2 SLE patients with high-risk aPL profile (persistently positive medium/high titres or 
multiple positivity) may receive primary prophylaxis with antiplatelet agents (2a/C), 
especially if other atherosclerotic/thrombophilic factors are present, after balancing the 
bleeding hazard. 
9.45 (0.80) 
4.1.3 For secondary prevention (thrombosis, pregnancy complication/loss), the therapeutic 
approach should be the same as for primary anti-phospholipid syndrome (1b/B). 10.0 (0) 
4.2 Infectious diseases  
4.2.1 SLE patients should be assessed for general and disease-related risk factors for 
infections, such as advanced age/frailty (–/D), diabetes mellitus (–/D), renal 
involvement (2b/B), immunosuppressive/biologic therapy (1b-2b/B-C) and use of GC 
(1a/A). 
9.85 (0.65) 
4.2.2 General preventative measures (including immunizations) and early recognition and 
treatment of infection/sepsis are recommended (–/D). 9.90 (0.44) 
4.3 Cardiovascular disease  
4.3.1 Patients with SLE should undergo regular assessment for traditional (1b/B-C) and 
disease-related risk factors for cardiovascular disease, including persistently active 
disease (1b/B), increased disease duration (1b/A), medium/high titres of aPL (1b/A), 
renal involvement (1b/B) (especially, persistent proteinuria and/or GFR <60 ml/min) 
and chronic use of GC (1b/B). 
9.85 (0.65) 
4.3.2 Based on their individual cardiovascular risk profile, SLE patients may be candidates 
for preventative strategies as in the general population, including low-dose aspirin 
(2b/D) and/or lipid-lowering agents (2b/D).  
9.85 (0.48) 
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Results and Discussion 
Overarching principles 
SLE represents a challenge for the treating physician in terms of diagnosis and treatment. Its protean 
manifestations, often multisystem but occasionally limited to a few or single organ, have led some 
physicians to focus exclusively on evidence of serologic autoimmunity [antinuclear (ANA) and more 
specific autoantibodies], for a disease where diagnosis is clinical after excluding competing diagnoses. 
Monitoring of SLE through validated disease activity and chronicity indices, including physician global 
assessment (PGA), is recommended.  For patients with severe disease, multidisciplinary care in dedicated 
lupus centres is desirable.9 Immunosuppressive (IS) therapy (for induction and maintenance of remission) is 
indicated in organ-threatening lupus.   
 
Recommendations 
Goals of treatment 
To improve long-term patient outcomes, management should aim at remission of disease symptoms and 
signs, prevention of damage accrual and minimisation of drug side-effects, as well as improvement of 
quality of life.10,11 Complete remission (absence of clinical activity with no use of GC and IS drugs) is 
infrequent.12-16 To this end, newly defined low disease activity states (based on a SLEDAI score ≤ 3 on 
antimalarials, or alternatively SLEDAI ≤ 4, PGA ≤1 with GC ≤7.5 mg of prednisone and well tolerated IS 
agents) have shown comparable rates with remission, regarding halting of damage accrual (OR 0.5-0.7 for 
increase in damage index) and prevention of flares.14,17-20 Accordingly, treatment in SLE should aim at 
remission or, if this state cannot be achieved, at low disease activity in all organ systems. In lupus nephritis 
(LN), therapy should aim at least partial remission [defined as ≥50% reduction in proteinuria (UPr) to 
subnephrotic levels and serum creatinine (SCr) within 10% from baseline] by 6-12 months; complete renal 
remission (proteinuria <500 mg/24hr and SCr within 10% from baseline), however, may require longer 
treatment duration, often more than 12 and until 24 months. In monitoring renal response, reduction of UPr 
(to less than 0.8 gm/d) following treatment is more important than residual haematuria.21 Patients with more 
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severe proteinuria and longer-standing disease are less likely to respond or show more delayed 
responses.22,23 
Prevention of disease flares is an additional milestone of SLE treatment. Although a universally accepted 
definition is lacking, most experts agree that a flare is a measurable increase in disease activity usually 
leading to change of treatment.24 Flares are common in the disease course and contribute significantly to 
organ damage accrual and worse outcome.17,25,26 Consistently reported risk factors for a higher disease flare 
rate include younger age at disease onset, no use of antimalarials, persistent generalized disease activity and 
serologic activity (anti-dsDNA, low complement).27-31 Assessment of adherence to drug treatment, close 
monitoring and optimisation of disease control in these patients may reduce the risk for a flare.  
 
Treatment of SLE 
i) Hydroxychloroquine 
Hydroxychloroquine (HCQ) is recommended for all patients with SLE. There is evidence for multiple 
beneficial effects of HCQ in SLE,32 yet  poor adherence to treatment is not uncommon.33-35 Drug blood 
levels can be used to assess compliance,33,35 but data are currently insufficient to recommend routine 
monitoring of drug levels. Concerns for retinal toxicity with long-term HCQ therapy led to the use of more 
sensitive screening techniques, with a prevalence of retinal abnormalities exceeding 10% after 20 years of 
continuous use.36,37 Major risk factors for retinopathy include duration of treatment (OR 4.71 for every 5 
years of use), dose (OR 3.34 for every 100 mg daily dose), chronic kidney disease (adjusted OR 8.56) and 
preexisting retinal or macular disease.37 Based on existing evidence suggesting that the risk of toxicity is 
very low for doses below 5 mg/Kg real body weight, the daily dose should not exceed this threshold. Of 
note, efficacy of HCQ in lupus has been established in studies with a prescribed dose of 6.5 mg/Kg/day, thus 
it remains to be confirmed whether a lower dose will have comparable clinical effects. Patients in long-
standing remission may have their dose lowered, although no studies have formally addressed this strategy. 
The choice of quinacrine, an alternative antimalarial, can be considered in patients with cutaneous 
manifestations and HCQ-induced retinal toxicity. 
 
ii) Glucocorticoids 
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GC can provide rapid symptom relief, but the medium to long-term aim should be to minimize daily dose to 
≤ 7.5 mg/day prednisone equivalent or to discontinue them, because long-term GC therapy can have various 
detrimental effects including irreversible organ damage.38-41 Risks are substantially increased at continuous 
GC doses above 7.5 mg/day, with some studies suggesting that also lower doses might be harmful.17,42-44 To 
this end, two approaches can be considered: i) use of pulses of intravenous methylprednisolone (IV MP) of 
various doses (depending on severity and body weight), which take advantage of the rapid non-genomic 
effects of GC45 and may allow for a lower starting dose and faster tapering of PO GC46,47, and ii) early 
initiation of immunosuppressive agents, to facilitate tapering and eventual discontinuation of oral GC (see 
below). High-dose IV MP (usually 250 to 1000 mg/day for 3 days) is often used in acute, organ-threatening 
disease (e.g. renal, neuropsychiatric) after excluding infections.48  
 
iii) Immunosuppressive (IS) drugs  
Consequent initiation of IS drugs facilitates a more rapid GC tapering and may prevent disease flares.49 The 
choice of agent depends on prevailing disease manifestation(s), patient age and childbearing potential, safety 
concerns and cost. Methotrexate (MTX) and azathioprine (AZA) should be considered in patients with poor 
symptom control after a trial with GC and HCQ or when HCQ alone is unlikely to be sufficient, due to the 
large experience gained with their use and their relatively safe profile.50 Published evidence is generally 
stronger for MTX than AZA, yet the latter is compatible with pregnancy contemplation. Mycophenolate 
mofetil (MMF) is a potent immunosuppressant with efficacy in renal and non-renal lupus (although not in 
neuropsychiatric disease).51-53 In a recent randomized, open-label trial in extrarenal SLE, enteric-coated 
mycophenolate sodium (EC-MPS) was superior to AZA in achieving remission and reducing flares.54 
However, its teratogenic potential (needs to be discontinued at least 6 weeks before conceiving), along with 
its higher cost compared to AZA or MTX, poses a limitation towards universal recommendation in women 
of reproductive age with non-renal manifestations. Cyclophosphamide (CYC) can be considered in organ-
threatening disease (especially renal, cardiopulmonary or neuropsychiatric) and only as rescue therapy in 
refractory non-major organ manifestations; due to its gonadotoxic effects, it should be used with caution in 
women and men of fertile age.55-57 Concomitant use of GnRH analogs attenuates the depletion of ovarian 
reserve associated with CYC therapy and is recommended in premenopausal SLE patients.4,58,59 Information 
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about the possibility of ovarian cryopreservation should be offered ahead of treatment. Other risks of CYC 
therapy such as malignancy and infections should also be considered.60,61 
 
iv) Biologic agents 
There is evidence to support beneficial effects of B-cell targeting agents in SLE.62-66 Belimumab should be 
considered in extrarenal disease with inadequate control (ongoing disease activity or frequent flares) to first-
line treatments (typically including combination of HCQ and prednisone with or without IS agents), and 
inability to taper GC daily dose to acceptable levels (i.e. maximum 7.5 mg/day). Patients with persistent 
disease may benefit from belimumab; more likely to respond are patients with high disease activity (e.g. 
SLEDAI >10), prednisone dose >7.5 mg/day and serologic activity (low C3/C4, high anti-dsDNA titres), 
with cutaneous, musculoskeletal and serologic manifestations responding the most.67-69 
Due to the negative results of randomized controlled trials (RCT), rituximab (RTX) is currently only used 
off-label, in patients with severe renal or extrarenal (mainly hematological and neuropsychiatric) disease 
refractory to other IS agents and/or belimumab, or in patients with contraindications to these drugs. As a 
general rule, more than one IS drug need to have failed prior to RTX administration,70-73 except perhaps for 
cases of severe autoimmune thrombocytopenia and hemolytic anemia, wherein RTX has demonstrated 
efficacy both in lupus and in patients with isolated immune thrombocytopenia (ITP).74-76 In lupus nephritis, 
RTX is typically considered following failure of first-line therapies (CYC, MMF) or in relapsing disease.70,77 
More recently, a post hoc analysis of the LUNAR trial showed that complete B-cell depletion following 
RTX treatment in LN was associated with higher odds for complete response at 78 weeks.78 
Figure 1 summarizes the various drugs used in the treatment of SLE, according to disease severity 
stratification. Supplementary Table 5 outlines the recommended doses of the drugs mentioned in the 
manuscript. 
 
Specific manifestations 
i) Skin disease 
A large body of evidence originates from studies in patients with cutaneous lupus erythematosus (CLE). 
Effective protection from ultraviolet exposure with broad-spectrum sunscreens and smoking cessation are 
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strongly recommended.79-81 In atypical or refractory cases, a diagnostic skin biopsy should be considered. 
First line treatment of skin disease includes topical agents (GC and/or calcineurin inhibitors) and 
antimalarials, with or without systemic GC (the latter at a starting dose depending on severity of skin 
involvement).82,83 HCQ is the antimalarial of choice over chloroquine due to its multiple beneficial effects 
and possibly lower risk for retinal toxicity;84 in cases of inadequate response or evidence of toxic 
retinopathy, quinacrine (mepacrine) may be used as an add-on or sequential therapy, respectively. 85-87 Albeit 
quinacrine is currently unavailable in several countries worldwide, it is a useful alternative when available. 
There are no studies examining retinal toxicity of quinacrine with the newer, more sensitive screening 
techniques (visual fields or optical coherence tomography), however with current knowledge, retinopathy is 
not considered a side-effect of quinacrine. 
A sizeable proportion (almost 40%) of patients will not respond to first-line treatment.86,88 In such cases, 
MTX can be added.50,89 Other agents include retinoids, dapsone and MMF or EC-mycophenolic acid 79,90,91. 
Belimumab and RTX have also shown efficacy in mucocutaneous manifestations of SLE, although these 
studies have not included a validated activity score for skin lesions; RTX may be less efficacious in chronic 
forms of skin lupus.62,92-94 Thalidomide is effective in various subtypes of cutaneous disease.95,96 Due to its 
strict contraindication in pregnancy, the risk for irreversible polyneuropathy, and the frequent relapses upon 
drug discontinuation, it should be considered only as a “rescue” therapy in patients who have failed multiple 
previous agents. A treatment algorithm for the various subtypes of cutaneous lupus erythematosus has been 
published by a European group of Dermatologists guided by the European Dermatology Forum in 
cooperation with the European Academy of Dermatology and Venereology. [79] 
 
ii) Neuropsychiatric disease (NPSLE) 
Attribution of neuropsychiatric manifestations to SLE often requires a comprehensive, multidisciplinary 
approach to rule out mimics (infections, malignancy and others), taking into account the presence of risk 
(“favoring”) factors [type and timing of manifestation, presence of generalized, non-neurological disease 
activity, abnormal neuroimaging and cerebrospinal fluid analysis, positive antiphospholipid antibodies 
(aPL)],97 as well as confounding factors favoring alternative diagnoses.98 The use of validated attribution 
models may aid in the diagnostic process.99,100 
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Treatment of NPSLE depends on whether the underlying pathophysiologic mechanism is presumed to be 
inflammatory or embolic/thrombotic/ischemic.2,101 GC and/or IS agents should be considered in the former, 
while anticoagulant/antithrombotic treatment is favored when aPL antibodies are present.102-107 Distinction 
between the two pathophysiologic processes may not be easy in clinical practice, or the two processes may 
coexist in the same patient.2 Combination of IS and anticoagulant/antithrombotic therapy may be considered 
in these patients. SLE patients with cerebrovascular disease should be managed like the general population 
in the acute phase; in addition to controlling extra-CNS lupus activity, IS therapy may be considered in the 
absence of aPL antibodies and other atherosclerotic risk factors or in recurrent cerebrovascular events.108 In 
this context, neuroimaging and/or CSF studies may provide additional supporting evidence for 
immunosuppressive therapy. Targeted symptomatic therapy is indicated according to the type of 
manifestation (eg. antipshychotics for psychosis, anxiolytics for anxiety disorder etc). 
 
ii) Haematological disease 
Haematological manifestations frequently necessitating anti-inflammatory/immunosuppressive treatment in 
SLE patients include thrombocytopenia and autoimmune hemolytic anemia (AIHA). First-line treatment of 
significant lupus thrombocytopenia (platelet count below 30,000/mm3) consists of moderate/high doses of 
GC in combination with IS agent (AZA, MMF or cyclosporine; the latter having the least potential for 
myelotoxicity) to facilitate GC-sparing. Initial therapy with pulses of IV MP (1 to 3 days) is encouraged. 
Intravenous immunoglobulin (IVIG) may be considered in the acute phase, in cases of inadequate response 
to high-dose GC or to avoid GC-related infectious complications.  
Treatment of thrombocytopenia is typically lengthy and often characterized by relapses during GC 
tapering.109 In patients with no response to GC (i.e. failure to reach a platelet count > 50,000/mm3) or 
relapses, RTX should be considered, considering also its efficacy in ITP.74,76,110 CYC may also be considered 
in such cases. Thrombopoietin agonists or splenectomy should be reserved as last options.111,112 
Autoimmune hemolytic anemia (AIHA) is far less common than thrombocytopenia in SLE; its treatment 
follows the same principles regarding use of GC, IS drugs and RTX. Autoimmune leukopenia is common in 
SLE but rarely needs treatment; careful work-up is recommended to exclude other causes of leukopenia 
(especially drug-induced). 
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iv) Renal disease 
Patients at high risk of developing renal involvement (males, juvenile lupus onset, serologically active 
including positivity for anti-C1q antibodies)113-115 should be under vigilant monitoring (e.g. at least every 3 
months) to detect early signs of kidney disease. Following diagnosis, secured with a kidney biopsy, 
treatment of LN includes an initial induction phase, followed by a more prolonged maintenance phase. 
MMF and CYC are the IS agents of choice for induction treatment; low-dose CYC (Euro-Lupus regimen, 
Supplementary Table S5) is preferred over high-dose CYC as it has comparable efficacy and lower risk of 
gonadotoxicity.57,116,117 Published data support the use of MMF and high-dose CYC (Supplementary Table 
S5) in severe forms of LN associated with increased risk of progression into end-stage renal disease (ESRD) 
[reduced glomerular filtration rate (GFR), histologic presence of fibrous crescents or fibrinoid necrosis, or 
tubular atrophy/interstitial fibrosis].118,119 An early significant drop in UPr (to ≤1 gr/day at 6 months or ≤0.8 
gr/day at 12 months) is a predictor of favorable long-term renal outcome.21,117,120 MMF or AZA may be used 
as maintenance therapy, with the former associated with fewer relapses;121,122 the choice depends on the 
agent used for induction phase and on patient characteristics, including age, race and wish for pregnancy. In 
refractory or relapsing disease, RTX may be considered. 
Following the EULAR recommendations for LN in 2012, several studies have been published regarding the 
use of calcineurin inhibitors (CNIs) to treat proliferative LN, either alone or in the form of a “multitarget 
therapy” (combination of tacrolimus with MMF).123-127 These studies were performed almost exclusively in 
Asian populations and had short follow-up hence data have to be corroborated with longer duration studies 
in multiethnic populations. To this end, at present, CNIs may be considered as second-line agents for 
induction or maintenance therapy mainly in membranous LN, podocytopathy, or in proliferative disease with 
refractory nephrotic syndrome, despite standard-of-care within 3-6 months;128,129 in the latter case, they may 
be used alone or in combination with MMF, since small, observational studies have shown the CNI/MMF 
combination to be effective in disease refractory to standard therapy.130-132 Monitoring SCr and blood levels 
of CNI to avoid chronic drug toxicity is essential.   
 
Comorbidities 
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i) Antiphospholipid antibodies (aPL) and Antiphospholipid syndrome (APS) 
The presence of aPL is associated with thrombotic and obstetric complications, and increased risk of damage 
accrual.133,134 In aPL carriers, a recent meta-analysis supported a protective role of low-dose aspirin for 
primary prophylaxis against thrombosis in the subgroup of aPL carriers who had SLE;135 however, in view 
of the potential bleeding hazard,136,137 it is not clear whether this should be applied to lupus patients with any 
aPL antibodies or only to those carrying a high risk aPL profile (ie. triple aPL positivity, lupus anticoagulant 
or high titers of anti-cardiolipin antibodies).138 SLE patients with aPL may also receive additional 
anticoagulant treatment, such as low-molecular weight heparin, during high-risk periods for thrombosis 
(pregnancy or postoperatively), although no studies have formally addressed this question. 
No studies have been performed exclusively on SLE-APS patients, with several studies excluding secondary 
APS due to lupus. Thus, with current knowledge, treatment of APS in the context of SLE should not differ 
from treatment of primary APS. A recent randomized, open-label trial comparing rivaroxaban to warfarin in 
APS with triple aPL positivity (~21% of patients had SLE-APS) was prematurely terminated due to an 
excess of thromboembolic events in the rivaroxaban arm.139 Thus, in patients with SLE-APS, use of novel 
oral anticoagulants for secondary prevention should be avoided; however, they could potentially serve as an 
alternative option in selected patients (low-risk aPL profile, no history of arterial thrombotic events) with 
difficult to control international normalized ratio on warfarin, after balancing possible risks. 
 
ii) Infections 
Risk of infection in SLE is associated with both disease-related and treatment-related factors; high-dose GC 
therapy, CYC, MMF and RTX are all associated with an increased risk for infection, while high disease 
activity, severe leukopenia and presence of renal involvement (± hypogammaglobulinemia in nephrotic 
syndrome) also contribute independently.48,140-143 Protection against infections should be proactive, focusing 
both on primary prevention, as well as timely recognition and treatment. Lupus patients should receive 
vaccinations according to the EULAR recommendations for vaccination of patients with autoimmune 
rheumatic diseases.144,145 Immunization against seasonal influenza and pneumococcal infection (both PCV13 
and PPSV23) should be strongly considered, preferably during stable disease. Herpes zoster vaccination is 
now available for the general population, but a study in SLE has not been performed. Prompt diagnosis and 
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treatment of sepsis is essential. To this end, validated scores such as the quick SOFA [(systolic blood 
pressure ≤100 mmHg, respiratory rate ≥22/min, altered mental state with Glasgow coma scale < 15):  the 
presence of ≥ 2 points near the onset of infection is associated with a greater risk of death or prolonged 
intensive care unit stay] may identify patients who are at greater risk for a poor outcome.146 
 
iii) Cardiovascular disease 
SLE is an independent risk factor for cardiovascular disease (CVD), due to both traditional and disease-
related risk factors, such as persistent disease activity, LN, presence of aPL and use of GC.147-149 Surrogate 
measures of atherosclerosis, such as carotid plaques, carotid intima media thickness (cIMT) and coronary 
artery calcium (CAC) are frequently used to identify subclinical CVD in SLE.150 Low-dose aspirin may be 
considered for primary prevention of CVD, as it may reduce the risk for incident CVD in SLE (HR 0.24 in 
one retrospective study).151,152 However, this has to be viewed in light of recent large studies in diabetics and 
elderly showing that the benefits of aspirin for primary CVD prevention are counterbalanced by the larger 
bleeding hazard.136,153 The value of statins in SLE has been tested in RCTs, which failed to show a clear 
benefit over placebo, when cIMT was used a surrogate marker for CVD.154,155 Thus, routine use of statins is 
not recommended for all patients but should be considered on the basis of lipid levels and the presence of 
other traditional risk factors. Calculation of the 10-year CVD risk using the Systematic Coronary Risk 
Evaluation (SCORE, https://www.escardio.org/Education/Practice-Tools/CVD-prevention-toolbox/SCORE-
Risk-Charts) is recommended,156 although the actual risk is underestimated in patients with SLE.  
Certain points to consider and the research agenda suggested by the Task Force Members are reported in 
Table 2. These points aim to improve the design of clinical studies in order to answer clinically important 
questions, for which the current “state-of-the-art” is insufficient. In particular, data regarding the optimal 
duration and timing of discontinuation of therapy in both renal and extrarenal disease are scarce;157 for the 
former, recent studies support the value of a repeat kidney biopsy for the management of maintenance 
therapy, but more data are needed.158,159 
 
Table 2. Future research agenda in SLE 
 
  19
Targets of therapy 
 Exploration of a universally accepted level of residual disease activity, if remission cannot be 
achieved 
Existing therapies and disease monitoring 
 Efficacy of CNI-containing treatment regimens in LN in different racial/ethnic groups and at 
longer time points 
 Usefulness of measurements of drug blood levels (HCQ, MMF etc) 
 Efficacy of quinacrine as immunomodulator in patients with HCQ-induced retinal toxicity. 
 Comparative trials of conventional IS drugs with global and organ-specific result reporting 
 Randomized trials testing lower cumulative dose glucocorticoid regimens versus conventional 
regimens 
 Optimal treatment regimen of RTX: Regular versus on-demand  
 Optimal duration of therapy and timing of discontinuation (renal and extrarenal disease) 
 Value of repeat kidney biopsy for monitoring LN and determination of clinical versus histologic 
response to therapy 
Pathophysiology and Biomarkers 
 Susceptibility to develop SLE 
 Involvement of particular organ systems over others, multisystem versus organ-dominant 
disease 
 Response to specific therapeutic agents over others (pharmacogenetics, transcriptomics etc) 
Clinical trial design and new drug development 
 Optimization of clinical trial design and study endpoints to maximize probability of new drug 
approval in SLE 
 Handling of background medication to avoid polypharmacy and “dilution” of positive effects of 
drugs under study  
 Inclusion of organ-specific endpoints and disease activity measures 
 Increase in number of adequately trained trial sites (recruitment, infrastructure and training)  
 Academia versus industry-driven clinical trials 
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Figure 1. Treatment of non-renal SLE – Recommended drugs with respective grading of 
recommendation 
 
aPL: Antiphospholipid antibodies; HCQ: Hydroxychloroquine; GC: Glucocorticoids; PO: Per os; IM: Intramuscular; 
IV: Intravenous; MTX: Methotrexate; AZA: Azathioprine; BEL: Belimumab; CNI: Calcineurin inhibitors; MMF: 
Mycophenolate mofetil; CYC: Cyclophosphamide; RTX: Rituximab; SLEDAI: Systemic Lupus Erythematosus 
Disease Activity Index; Pre: Prednisone 
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